HIMS Stock Plummets 0.16% as Trading Volume Dips to 51st in Rankings Amid Class-Action Lawsuit Allegations

On August 7, 2025, Hims & Hers Health (HIMS) closed with a 0.16% decline, trading with a daily volume of $1.66 billion, a 30.82% drop from the prior day’s activity. The stock ranked 51st in trading volume among listed equities, reflecting reduced short-term market engagement.

A class-action lawsuit filed by The Gross Law Firm has drawn attention to Hims’ business practices, alleging deceptive promotion of “knockoff versions of Wegovy®” and failure to disclose risks threatening its partnership with Novo Nordisk. The firm claims these actions created substantial uncertainty over the collaboration and misled investors. Shareholders who purchased HIMS between April 29 and June 23, 2025, are being invited to seek lead plaintiff status by August 25. The legal action highlights regulatory and reputational risks that could weigh on the company’s valuation and operational credibility.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to the present, outperforming the benchmark return of 29.18% by 137.53%. This underscores the role of liquidity concentration in short-term stock performance, particularly in volatile markets.